NCT07750678Not yet recruitingPhase 1/2
Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy
A Multicenter, Phase I/II, Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Intrastromal Injection of Genome-editing GEB-101 in Participants With TGFBI-related Corneal Dystrophy
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 2 Aug 2026
- Start date
- Oct 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- GenEditBio Limited
- NCT number
- NCT07750678
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 30
- From Oct 2026 to the primary completion date, Aug 2027
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior gene therapy administration in either eye.
- Active infection occurring or suspected within 4 weeks prior to the investigational product, requiring systemic anti-infective therapy.
Other illness
- In either eye: Have any active infection, glaucoma, corneal disease, or other ocular conditions that may affect the assessment of efficacy or safety.
- In the study eye: Have a history of specific intraocular or corneal surgery, or the presence of active intraocular inflammation or vitreous hemorrhage.
- Patient with other corneal disorders that may hinder therapeutic surgery or interfere with the interpretation of study results.
- Subjects with a history of major cardiovascular events within 6 months, the presence of any clinically significant condition, a diagnosis of malignancy within 5 years (with specified exceptions), or active infection with HIV, syphilis, hepatitis C, or hepatitis B.
- Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol.
Other
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Who the study is looking for
- Males or females, age 18-70 years (inclusive).
- TGFBI gene mutation confirmed.
- Patients with corneal dystrophy who are symptomatic.
- Willing and able to give signed informed consent and follow study instructions.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Eye & ENT Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| University of California Los Angeles (UCLA). Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.